“BIIB Soars: China Approves LEQEMBI® for Alzheimer’s!”

Landmark Approval & Market Reaction

Biogen’s Breakthrough in China: Biogen Inc. (NASDAQ: BIIB) and partner Eisai achieved a major milestone as China’s regulators approved LEQEMBI® (lecanemab) for early-stage Alzheimer’s disease ([1]) ([1]). This makes China the third country – after the U.S. and Japan – to greenlight the drug ([1]) ([1]). The approval, granted in January 2024, paved the way for a commercial launch in China by mid-2024 ([1]) ([1]). Investors greeted the news enthusiastically, as Alzheimer’s represents a vast untapped market – Eisai estimates 17 million people in China have mild cognitive impairment or early Alzheimer’s ([2]). BIIB’s stock price surged on hopes that LEQEMBI could become a blockbuster therapy in this huge patient pool. The drug is a monoclonal antibody that targets beta-amyloid plaques, and it’s the first approved treatment shown to slow Alzheimer’s disease progression ([1]). In China, LEQEMBI will initially be available on the private market at a steep cost (¥2,508 per 200mg vial, roughly \$345) ([2]). Eisai has partnered with a major Chinese insurer to improve affordability, aiming to drive uptake despite pricing and diagnostic hurdles ([2]).

Significance for Biogen: The China approval reinforces Biogen’s global Alzheimer’s strategy. In the U.S., LEQEMBI secured full FDA approval in July 2023, enabling Medicare coverage and triggering U.S. rollout ([1]). Japan approved it in September 2023 ([1]). China’s nod expands LEQEMBI’s addressable market to Asia, buoying investor sentiment that Biogen’s growth could reaccelerate after years of reliance on declining legacy drugs. Indeed, Biogen’s core multiple sclerosis (MS) franchise has been eroding amid generics and new competitors – 2024 sales of MS drugs (like Tecfidera and Tysabri) dropped ~8% year-over-year ([3]). LEQEMBI (co-marketed with Eisai) offers a critical new revenue stream to offset these declines. In Q2 2024, LEQEMBI generated \$40 million in U.S. sales (beating expectations) ([4]), and in Q1 2024 it posted \$19 million as patient uptake began ([5]). While initial U.S. growth was gradual – constrained by required diagnostic tests and safety monitoring – Biogen expects a “linear” ramp-up as awareness and infrastructure improve ([5]) ([5]). Approval in China (and anticipated EU approval by 2025) further bolsters the drug’s long-term sales potential. This positive news helped lift BIIB shares from multi-year lows. (Notably, Biogen’s stock had slid ~40% in 2024 amid earlier setbacks – including an initial EU rejection of lecanemab and disappointment around a partner’s depression drug ([6]) ([6]).) The China win, however, signaled a turnaround and was a catalyst for Biogen’s stock, reflecting revived confidence in the “new Biogen” pipeline. CEO Christopher Viehbacher (appointed late 2022) has emphasized Alzheimer’s and neurology innovations as key to Biogen’s future ([7]). LEQEMBI’s growing acceptance – alongside other new launches like Qalsody for ALS and Skyclarys for ataxia – suggests Biogen’s investment in R&D is starting to pay off.

Dividend Policy, Cash Flow & Shareholder Returns

No Dividend, Focus on R&D and Buybacks: Biogen notably does not pay a cash dividend – it has refrained from dividends since inception ([8]). Management currently has no intent to initiate dividends, preferring to reinvest in growth opportunities and pipeline development ([8]) ([8]). Instead of dividends, Biogen has occasionally used share repurchases to return capital. The Board authorized a \$5 billion buyback program in 2020, under which Biogen repurchased ~3.6 million shares (\$750 million worth) in 2022 ([8]). However, share buybacks were paused in 2023 and 2024 as the company preserved cash for strategic deals – no shares were repurchased in those years ([8]) ([8]). As of year-end 2024, about \$2.1 billion remained available under the buyback authorization for future repurchases ([8]). Biogen’s decision to hold off on buybacks makes sense given its recent acquisitions (discussed below) and the implementation of a new 1% excise tax on stock repurchases in the U.S. ([8]) ([8]). The company has indicated it continually reviews capital allocation options – including potential dividends or buybacks – but near-term cash was prioritized for pipeline investments and M&A ([8]) ([8]).

2025 Wealth Protection Guide

Elon Musk’s Dire Warning: $36T Debt Crisis May Hit Retirees Hardest

Washington’s spending could spark soaring rates and stock crashes — protect retirement accounts with a Self-Directed Gold IRA backed by physical gold.

Get Your FREE 2025 Wealth Protection Guide

Robust Cash Generation: Despite not returning cash via dividends, Biogen generates strong internal cash flows to fund its initiatives. In 2024, operating cash flow was \$2.88 billion ([8]), reflecting healthy profit conversion even as revenue was roughly flat (more on earnings below). This cash flow helped Biogen boost its cash reserves from \$1.0 billion at the end of 2023 to \$2.4 billion by December 2024 ([8]). The cash build was driven by earnings plus a \$437.5 million proceeds from selling Biogen’s stake in the Samsung Bioepis JV in April 2024 ([8]). Biogen deployed cash for deals like the \$1.15 billion acquisition of HI-Bio in mid-2024 ([8]), and also paid down debt (including a \$650 million term loan payoff) ([8]). Even after these uses, Biogen’s cash on hand comfortably supports ongoing R&D and any near-term obligations. The absence of a dividend actually gives Biogen financial flexibility, as it can channel cash into developing drugs (e.g. Alzheimer’s, lupus and immunology programs) or bolt-on acquisitions without worrying about a fixed payout commitment. For shareholders, this means the yield is effectively 0% ([9]), but value is expected to accrue through stock price appreciation as new drugs succeed, and potentially through opportunistic buybacks if the stock remains undervalued.

Debt, Leverage & Interest Coverage

Moderate Leverage, Staggered Maturities: Biogen carries a moderate debt load after recent acquisitions. As of Dec 31, 2024, the company had \$5.44 billion in notes payable and term loans outstanding, down from \$6.29 billion a year prior ([8]). This decrease reflects Biogen using cash to repay debt (including a 2023 term loan used for the Reata acquisition) in 2024. Biogen’s long-term debt stood at \$4.55 billion (excluding current maturities) at 2024 year-end ([8]), consisting of senior unsecured notes with maturities from 2030 to 2051 ([8]). Importantly, its nearest large maturity is a \$1.75 billion, 4.05% Senior Note due September 2025, which was reclassified to short-term debt on the 2024 balance sheet ([8]). Biogen has ample liquidity to handle this 2025 maturity – with \$2.4 billion cash on hand and ongoing cash generation, it could repay or refinance that note comfortably. Beyond 2025, the debt maturity profile is long-dated: Biogen’s next notes include \$1.5 billion due 2030, \$1.12 billion due 2045, \$1.5 billion due 2050, and a smaller \$700 million due 2051 (the latter from a 2021 exchange offer) ([8]) ([8]). The company also maintains a \$1.5 billion revolving credit facility (renewed in 2024 for 5 years) for additional liquidity; this revolver remained undrawn at year-end, while requiring Biogen to keep leverage within set limits ([8]).

Coverage & Credit Health: Biogen’s leverage ratios are reasonable for a biotech of its size. Net debt (debt minus cash) is roughly \$3.9 billion, which is under 1.5× its 2024 EBITDA (estimated) – indicating a manageable leverage level. Interest expense is well covered by earnings. In 2024, Biogen’s interest expense was \$250 million (gross), or \$182.7 million net after interest income ([8]). This is a small fraction of operating profit (2024 net income was \$1.63 billion ([8])) and only about 6% of cash from operations ([8]). In other words, EBIT/interest coverage is robust – well over 10×. Biogen’s interest costs did rise in 2024 vs. the prior year (when it actually had net interest income thanks to large cash balances pre-acquisition) ([8]). The increase was due to reduced cash (after funding deals) and higher rates, but going forward interest expense should decline: management guided for lower net interest expense in 2025 as cash builds back up (and as some high-rate debt gets repaid) ([8]). Major rating agencies consider Biogen’s debt investment-grade; the company’s stable cash flows from established drugs and growing contribution from new products support its credit profile. Furthermore, Biogen has been proactive in capital management – e.g., redeeming a \$1 billion note early in 2022 to reduce interest costs ([8]). With no dividend drain and intermittent buybacks, Biogen can devote cash to debt reduction as needed. Overall, financial leverage is not a red flag for BIIB – the company appears prudently geared, with ample coverage of interest obligations and a lengthy runway on principal repayments.

Earnings, Valuation & Peer Comparison

Recent Performance: Biogen’s overall earnings have been in flux, reflecting both headwinds in older franchises and investments in new ones. In 2024, total revenue was \$9.68 billion, a slight 1.6% decline from 2023 (which was already 3% lower than 2022) ([8]) ([8]). The top-line slippage is due to generic erosion of Tecfidera (an oral MS drug), pricing pressure on other MS therapies, and the winding down of Biogen’s stake in biosimilars. Despite flat-to-lower revenue, Biogen’s cost discipline and pipeline contributions boosted profitability in 2024: net income rose to \$1.63 billion (EPS \$11.18) from \$1.16 billion (EPS \$8.02) in 2023 ([8]) ([8]). This jump was aided by heavy cost cuts (“Fit for Growth” program targeting \$1 billion in savings ([3])) and one-time gains (e.g., sale of a priority review voucher). Biogen’s adjusted EPS for 2024 was \$16.47, excluding certain charges ([3]), and it guided \$15.25–\$16.25 for 2025 ([3]), implying a slight decline as MS headwinds persist. Still, 2024’s earnings rebound illustrated Biogen’s ability to defend margins even in a challenging period.

!
Urgent Checklist — Are You Ready?
Tap each item to reveal Porter’s quick take and recommended asset.
Rising interest costs

Interest payments now exceed major budget items — Porter says: consider high-quality stocks with pricing power.
Foreign dumping treasuries

When confidence falls, hard assets shine — small allocation to physical gold or insured storage recommended.
Tariff-driven price shocks

Inflation winners: companies that pass costs through with ease. Porter lists his picks in the briefing.

(function(){var root=document.currentScript?document.currentScript.parentNode:document.querySelector(‘.ps2-accordion');root.querySelectorAll(‘.toggle').forEach(function(b){b.addEventListener(‘click',function(){var t=document.getElementById(b.getAttribute(‘data-target'));if(!t) return;var open=t.style.display!='block';t.style.display=open?'block':'none';b.textContent=open?'Hide':'Show';})});})();

Valuation Metrics: At the current share price, Biogen’s valuation appears undemanding. BIIB trades at roughly 13×–14× trailing earnings, which is on the low end of its historical range ([10]) ([11]). In fact, by the end of 2024 the stock’s P/E had compressed to ~13.6 (down from over 32× at end-2023 when earnings were depressed) ([10]). This multiple is also modest relative to large-cap biotech peers – for example, Amgen and Gilead Sciences recently traded around 13–15× earnings, while the broader pharma industry averages in the high-teens. Biogen’s price-to-sales ratio is ~2.3× (market cap ~$22 billion / \$9.7 billion revenue), reflecting the market’s cautious outlook on near-term growth. Its EV/EBITDA is likewise in the high single-digits – a reasonable level that suggests BIIB is not overvalued. The lack of a dividend (0% yield) ([9]) also puts the onus on capital gains for investor returns. For a company with several high-risk, high-reward drugs in its portfolio, the low P/E indicates skepticism remains priced in. Arguably, Biogen’s valuation discounts the uncertainty in Alzheimer’s therapy adoption and the declining legacy products. Bulls note that if LEQEMBI and other new drugs ramp up successfully, earnings could grow and the multiple would compress further, making the stock look very cheap in hindsight. In July 2025, Biogen indeed raised its sales forecast and beat earnings estimates, citing momentum in new product launches ([12]) – news that helped lift the stock from its lows. With an enterprise value of about \$26 billion and a deep pipeline (including neurodegenerative and immunology drugs), Biogen could be an acquisition target itself at this valuation, although CEO Viehbacher has downplayed any need for a sale. For now, BIIB’s price reflects a “show me” story: investors will reward it with a higher multiple only if it proves LEQEMBI and pipeline assets can more than offset declines and drive growth.

Key Risks & Red Flags

Slow Uptake & Competition in Alzheimer’s: While LEQEMBI’s approvals are a breakthrough, its commercial uptake may be gradual and is not without risk. Even in the U.S., uptake has been slower than hoped due to burdensome requirements – patients must undergo diagnostic PET scans or lumbar punctures to confirm amyloid pathology and receive regular MRI monitoring for side effects ([5]) ([5]). LEQEMBI can cause ARIA (amyloid-related imaging abnormalities, e.g. brain swelling or microbleeds), which were highlighted on its label and in media reports. These safety concerns limit eligible patients (those on blood thinners, for example, may be excluded). If similar caution prevails in China, adoption might start modestly despite the large patient pool. Additionally, price and reimbursement pose challenges: at ~\$26,500 per year in the U.S. (and around \$20,000–\$30,000 internationally), LEQEMBI is expensive ([13]) ([13]). In China, unless national insurance adds coverage, only affluent patients or those with private insurance subsidies may afford it ([2]). A related risk is regulatory or public backlash over safety or cost – the initial EU rejection in mid-2024 (on safety grounds) showed that not all regulators are convinced the drug’s benefits outweigh its risks ([6]). Although the EU later recommended approval in late 2024 after re-examination, any unforeseen safety issues could hurt global confidence. Biogen and Eisai are also contending with competition: Eli Lilly’s similar amyloid-clearing antibody donanemab (Kisunla) won FDA approval in July 2024 ([13]) and Chinese approval by end-2024 ([14]). Donanemab showed comparable efficacy in slowing Alzheimer’s and has a key differentiator – a finite dosing regimen (patients can stop treatment once plaques clear) ([13]). Priced around \$32,000/year in the U.S. ([13]), Lilly’s drug could capture significant share of the same patient population. If donanemab or future competitors are seen as safer, more convenient, or more effective, LEQEMBI’s sales might undershoot expectations. In short, market penetration risk is high: Biogen is betting big on Alzheimer’s, but physician uptake, payer support, and patient acceptance remain uncertain.

Pipeline and M&A Integration Risks: Beyond Alzheimer’s, Biogen faces execution risks on multiple fronts. The company made a \$6.5 billion acquisition of Reata Pharmaceuticals in 2023 ([3]), gaining the FDA-approved rare disease drug Skyclarys (for Friedreich’s ataxia). While Skyclarys has launched (with \$81 million ex-U.S. sales in early 2024) ([8]) ([8]), Biogen must scale this therapy in a niche market and potentially pursue additional indications to justify the hefty price paid. Integration of Reata and the smaller HI-Bio deal will require effective management attention – any cultural clashes, talent losses or pipeline write-downs would be a red flag. Biogen’s past acquisitions have had mixed outcomes (e.g., its $3 billion buy of Nightstar in 2019 didn’t pan out as hoped). The company is also doubling down on depression through a partnership-turned-ownership with Sage Therapeutics. Biogen spent \$1.5 billion upfront in 2020 for a stake in Sage and rights to Zuranolone, a novel antidepressant. Unfortunately, in 2023 zuranolone (branded Zurzuvae) received a narrow FDA approval only for postpartum depression – missing the larger major depression indication due to lackluster trial data. This drastically reduced the drug’s commercial potential and sent Sage’s stock plunging. Biogen responded by proposing to buy out Sage’s remaining shares for \$442 million in early 2025 ([15]). While this move could consolidate assets (including Sage’s neuroscience pipeline) on the cheap, it underscores a risk of poor capital allocation – Biogen may be expending resources to salvage a troubled investment. If Zurzuvae’s uptake remains limited, Biogen will have to write off part of that investment. More broadly, R&D pipeline failure is an ever-present risk: Biogen is advancing candidates in lupus, ALS, Parkinson’s and more – any high-profile trial failure (like its Parkinson’s gene therapy trial that was halted) can dent the stock. For instance, in late 2022 Biogen discontinued certain ALS and gene therapy programs, taking impairments. Investors should watch for red flags such as escalating R&D spend without approvals, or pipeline delays that could prolong Biogen’s growth drought.

Bryce Paul

Bryce Paul — Crypto Insider

Co-host of Crypto 101 (14M+ streams). I track the smart money — and I found one lending-platform altcoin that's slipping at a bargain price.

Get Bryce's #1 Coin (Only $3)

Legacy Franchise Erosion: Biogen’s base business still relies heavily on treatments for multiple sclerosis and spinal muscular atrophy (SMA). These franchises are maturing under pressure. Oral MS drug Tecfidera lost U.S. exclusivity in 2020 and saw sales evaporate due to generics; even Biogen’s newer MS pill Vumerity struggles to gain share. Infused MS therapy Tysabri faces competition from Roche’s Ocrevus and Novartis’s Kesimpta, while patents for Tysabri start expiring in a few years (biosimilars are a looming threat). In SMA, Biogen’s once-blockbuster Spinraza (an intrathecal injection) is declining as patients switch to Novartis’s one-time gene therapy Zolgensma or Roche’s daily oral Evrysdi. In Q3 2024, Spinraza sales fell ~7% ([16]) as these alternatives grew. These trends pose a risk that core revenue will keep shrinking, potentially faster than Biogen projects. If LEQEMBI and other new products do not ramp up enough, Biogen could see overall revenue contract for a number of years. Management expects mid-single-digit revenue decline in 2025 ([3]), which could continue without additional successful launches. Another risk is pricing pressure: The U.S. Inflation Reduction Act will enable Medicare to negotiate prices on certain older drugs later this decade – Biogen’s MS drugs could be targets, further squeezing U.S. sales. Internationally, austerity measures and biosimilar adoption (e.g. for Biogen’s Rituxan biosimilar) also weigh on revenues ([3]). Declining cash flow from legacy products could constrain Biogen’s ability to fund new initiatives if not managed carefully.

Finally, macroeconomic and currency factors bear mention: Biogen derives ~45% of revenue outside the U.S., so a strong dollar hurt 2024 results and is forecast to be a headwind in 2025 ([3]). Moreover, biotech sector volatility or regulatory changes (e.g., drug pricing reform, clinical trial standards) can affect Biogen’s prospects in unpredictable ways. Investors should monitor these external factors alongside company-specific developments.

Outlook and Open Questions

Biogen’s China triumph with LEQEMBI is a clear validation of its Alzheimer’s strategy – but important questions remain as BIIB navigates this new chapter:

– Blockbuster or Niche? Will LEQEMBI achieve broad usage to become a true blockbuster, or will safety/cost constraints limit it to a niche therapy? Early U.S. uptake suggests steady but modest growth, and it’s unclear if easier administration (e.g., a newly approved subcutaneous injection form ([17])) can dramatically accelerate adoption. Investors will be watching prescription trends in 2024–2025 and whether the subcutaneous at-home injection option (approved by the FDA in Aug 2025) boosts patient numbers by improving convenience ([17]) ([17]). Additionally, how will physicians balance LEQEMBI’s risks and benefits in routine practice? Real-world outcomes and any adverse event reports will shape the drug’s reputation. The competitive dynamic with Lilly’s donanemab is another open question – if donanemab’s “finite dosing” proves popular with neurologists, LEQEMBI might need differentiation (such as better long-term data or a lower price) to maintain market share.

– Reimbursement & Market Access: Particularly in China and other international markets, will public insurance systems cover LEQEMBI? China’s approval was swift, but getting the drug listed on the national reimbursement drug list (NRDL) at an affordable price could make years of difference in sales. If China’s government negotiates a big price cut for volume (as it often does), Biogen/Eisai might face margin trade-offs. In the U.S., Medicare is covering LEQEMBI, but with requirements like patient registries – will those barriers ease over time? Europe’s decision in early 2025 to approve lecanemab (after initial hesitation) opens another major market, but how each country’s health system responds (some may wait for cost-effectiveness data) is uncertain. Essentially, the pace of global market access – reimbursement timelines, price negotiations, and guideline inclusion – is a critical unknown that will dictate the drug’s revenue trajectory.

– Pipeline Progress: Can Biogen’s next wave of drugs deliver? Open questions include the fate of its lupus drug (dapirolizumab pegol or BIIB059) – can it succeed in Phase III and reach market in a competitive autoimmune field? Also, Biogen is trialing tau-targeting Alzheimer’s therapies (to complement amyloid drugs) – could these yield a follow-on product to LEQEMBI? The outcome of ongoing trials (e.g., in Parkinson’s disease, ALS with a broader ASO, depression, stroke, etc.) will determine Biogen’s long-term growth potential beyond 2025. Given the company’s mixed R&D track record (some high-profile failures like aducanumab’s commercial flop, but also successes like Spinraza), there is inherent uncertainty in how much of the current pipeline will translate to commercial products.

– Strategic Moves & Capital Allocation: Under CEO Viehbacher, Biogen has so far favored bolt-on acquisitions in neurology/rare diseases (Reata, Sage deal proposal, HI-Bio) rather than mega-mergers. Will this approach continue, and can Biogen integrate these acquisitions to extract value? CEO commentary suggests no immediate need for large M&A ([7]), yet Biogen’s growth gap in the back half of the decade might prompt further deal-making. An open question is whether Biogen will reinstate share buybacks (or consider an inaugural dividend) once LEQEMBI revenue scales up. With \$2.1 billion still authorized for repurchase ([8]), if the stock remains undervalued, management could return to buybacks as soon as cash flows stabilize post-2025. Conversely, if Biogen finds attractive pipeline assets to buy, it may conserve cash or even take on new debt – altering the capital return calculus. Investors will be looking for signals of capital allocation shifts (e.g., an update to the buyback program or any dividend discussion, which would mark a big change in policy).

In sum, Biogen’s near-term outlook hinges on flawless execution of its Alzheimer’s launch globally and careful stewardship of its existing products. The upside scenario is compelling – if LEQEMBI gains wide adoption (becoming a standard of care for early Alzheimer’s) and upcoming trial readouts are positive, Biogen could return to solid topline growth, with the stock likely re-rating higher. In this scenario, shareholders benefit from both earnings expansion and multiple expansion. However, the downside risks are non-trivial: clinical or commercial setbacks could keep revenues flat or declining, prolonging Biogen’s undervaluation or even compressing earnings further. The China approval is a big step forward, but it’s only one piece of the puzzle. Investors should keep a close watch on prescription metrics, competitive developments (like Lilly’s progress and any new entrants targeting Alzheimer’s), and Biogen’s pipeline milestones through 2025. BIIB’s story is evolving quickly – today’s low valuation could either be a value opportunity if things go right, or a value trap if challenges prove insurmountable. The coming year will be telling as to which way Biogen’s fortunes turn, but for now, the China LEQEMBI approval is a noteworthy victory that has injected optimism into this veteran biotech’s narrative ([2]).

Sources

  1. https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-approved-treatment-alzheimers-disease-china
  2. https://reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-launch-alzheimers-drug-leqembi-china-2024-06-28/
  3. https://reuters.com/business/healthcare-pharmaceuticals/drugmaker-biogen-forecasts-2025-profit-below-expectations-2025-02-12/
  4. https://reuters.com/business/healthcare-pharmaceuticals/biogen-lifts-2024-profit-forecast-hopes-new-product-launches-2024-08-01/
  5. https://reuters.com/business/healthcare-pharmaceuticals/biogen-beats-quarterly-profit-estimates-alzheimers-drug-sales-jump-2024-04-24/
  6. https://reuters.com/business/healthcare-pharmaceuticals/shares-japans-eisai-tumble-after-eu-rejects-alzheimers-drug-2024-07-29/
  7. https://reuters.com/business/healthcare-pharmaceuticals/biogen-ceo-sees-no-burning-need-more-acquisitions-2025-01-14/
  8. https://investors.biogen.com/node/28856/html
  9. https://tipranks.com/stocks/biib/dividends
  10. https://companiesmarketcap.com/hkd/biogen/pe-ratio/
  11. https://new.macrotrends.net/stocks/charts/BIIB/biogen/pe-ratio
  12. https://investing.com/news/stock-market-news/biogen-raises-annual-profit-estimates-on-strong-demand-for-rare-disease-drugs-4162251
  13. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lillys-alzheimers-drug-2024-07-02/
  14. https://reuters.com/business/healthcare-pharmaceuticals/eli-lillys-alzheimers-treatment-approved-china-2024-12-18/
  15. https://reuters.com/markets/deals/biogen-proposes-buy-remaining-stake-sage-442-million-deal-2025-01-10/
  16. https://reuters.com/business/healthcare-pharmaceuticals/biogen-lifts-annual-profit-forecast-cost-cuts-help-2024-10-30/
  17. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/

For informational purposes only; not investment advice.